Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization
Nina Pilat, … , Fritz Wrba, Thomas Wekerle
Nina Pilat, … , Fritz Wrba, Thomas Wekerle
Published May 19, 2016
Citation Information: JCI Insight. 2016;1(7):e85911. https://doi.org/10.1172/jci.insight.85911.
View: Text | PDF
Research Article Immunology Transplantation

Incomplete clonal deletion as prerequisite for tissue-specific minor antigen tolerization

  • Text
  • PDF
Abstract

Central clonal deletion has been considered the critical factor responsible for the robust state of tolerance achieved by chimerism-based experimental protocols, but split-tolerance models and the clinical experience are calling this assumption into question. Although clone-size reduction through deletion has been shown to be universally required for achieving allotolerance, it remains undetermined whether it is sufficient by itself. Therapeutic Treg treatment induces chimerism and tolerance in a stringent murine BM transplantation model devoid of myelosuppressive recipient treatment. In contrast to irradiation chimeras, chronic rejection (CR) of skin and heart allografts in Treg chimeras was permanently prevented, even in the absence of complete clonal deletion of donor MHC-reactive T cells. We show that minor histocompatibility antigen mismatches account for CR in irradiation chimeras without global T cell depletion. Furthermore, we show that Treg therapy–induced tolerance prevents CR in a linked suppression–like fashion, which is maintained by active regulatory mechanisms involving recruitment of thymus-derived Tregs to the graft. These data suggest that highly efficient intrathymic and peripheral deletion of donor-reactive T cells for specificities expressed on hematopoietic cells preclude the expansion of donor-specific Tregs and, hence, do not allow for spreading of tolerance to minor specificities that are not expressed by donor BM.

Authors

Nina Pilat, Benedikt Mahr, Lukas Unger, Karin Hock, Christoph Schwarz, Andreas M. Farkas, Ulrike Baranyi, Fritz Wrba, Thomas Wekerle

×

Figure 2

Treg but not 3 Gy irradiation treatment induces full immunological tolerance toward non-MHC antigens in mixed chimeras.

Options: View larger image (or click on image) Download as PowerPoint
Treg but not 3 Gy irradiation treatment induces full immunological toler...
(A and B) Donor-specific tolerance was assessed by grafting of donor-type fully mismatched (BALB/c) or MHC-mismatched (B10.D2) skin and heart 4–6 weeks after BMT. Classification of (A) skin allograft pathology and (B) heart allograft rejection scores for fully mismatched (3 Gy, n = 6; Tregs, n = 7) and MHC-mismatched grafts (3 Gy, n = 6) are shown. Fisher′s exact test was used to compare rejection scores between groups. Data are representative of at least 2 independent experiments. (C) Representative histology from 3-Gy skin grafts (>120 days after skin grafting; H&E staining magnification ×200) for fully mismatched grafts (Balb/c, left) and MHC mismatched grafts (B10.D2, right; n = 6/group) is shown.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts